Trial Information

Summary: Advanced Non-small Cell Lung Cancer Study CASA404A2301

The purpose of this study is to determine if adding the study drug ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with newly diagnosed advanced non-small cell lung cancer. The standard chemotherapy regimen that all patients receive in this study is paclitaxel plus carboplatin. Participants will also receive either ASA404 or a placebo (half will receive ASA404, half will receive placebo). The study drug ASA404 is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Participants will receive a maximum of 6 cycles of study treatment. Each treatment cycle is 21 days (3 weeks) long. Participants will return to their doctor's office every 3 weeks so that their condition can be monitored. The number of treatment cycles for each participant depends on how they respond to treatment and whether they suffer from any side effects.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 21, 2008 at 2:56:16 PM